Potential and Clinical Translation of Oncolytic Measles Viruses.

Related Articles

Potential and Clinical Translation of Oncolytic Measles Viruses.

Expert Opin Biol Ther. 2017 Jan 27;:

Authors: Robinson S, Galanis E

Abstract
INTRODUCTION: Oncolytic viruses represent a novel treatment modality that is unencumbered by the standard resistance mechanisms limiting the therapeutic efficacy of conventional antineoplastic agents. Attenuated engineered measles virus strains derived from the Edmonston vaccine lineage have undergone extensive preclinical evaluation and have demonstrated an ability to infect, resulting in antitumor effect with a broad variety of malignancies. They have laid the foundation for multiple future clinical trials in both solid and hematologic malignancies, which have demonstrated safety, biologic activity and the ability to elicit antitumor immune responses. Areas covered: This review examines the published preclinical data which justifies the clinical translation of this therapeutic platform, explores the available clinical trial data and expands on ongoing phase II testing. It also looks at approaches to optimize clinical applicability and offers future perspectives. Expert opinion: Reverse genetic techniques have allowed for the generation of oncolytic MV strains retargeted to increase viral tumor specificity and are equipped to express therapeutic and immunomodulatory genes to enhance anti-tumor efficacy. Continuous efforts focused on exploring methods to overcome resistance pathways and determining optimal combinatorial strategies will facilitate further capitalization of this encouraging antitumor strategy.

PMID: 28129716 [PubMed - as supplied by publisher]

http://ift.tt/2kg1fwW